News

How One Rheumatology Practice Bolstered Uptake Of Biosimilar Infliximab

Originally published in Biosimilar Development by Anna Rose Welch, Editor It never ceases to excite me when I hear that some organization, hospital, or clinic has found a way to bring biosimilars to its patients — regardless of all the noise happening in the industry today. Though I imagine there are more patients being treated […]

How One Rheumatology Practice Bolstered Uptake Of Biosimilar Infliximab Read More »

Why This Biosimilar Initiative In Rheumatology Is One To Watch

Originally published in Biosimilar Development by Anna Rose Welch, Editor Generally speaking, when it comes to fixing or advancing the U.S. healthcare system, it’s easier said than done. Look no further than the endless slew of proposed legislation that has, more often than not, been struck down in recent months. While in the EU, it’s

Why This Biosimilar Initiative In Rheumatology Is One To Watch Read More »

TSI Healthcare Hosts Inaugural Rheumatology User Group Meeting

TSI Healthcare, the national leader in the sales and support of customized rheumatology specific solutions, hosted its inaugural Rheumatology User Group Meeting August 2-3, 2019 in its home state of North Carolina. This meeting was the first of its kind for independent rheumatologists and other rheumatology professionals. CHAPEL HILL, N.C., August 15, 2019 /PRNewswire-PRWeb/ — TSI Healthcare,

TSI Healthcare Hosts Inaugural Rheumatology User Group Meeting Read More »

Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG

Originally published in The Center for Biosimilars Biosimilars have struggled to gain ground in the United States, with few products launched, relatively low uptake of commercially available products, formulary restrictions that sometimes favor branded biologics over biosimilar options, and exclusionary contracting practices that block biosimilars from formularies altogether. A variety of policy proposals have been put forward to help

Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG Read More »

Rheumatologists Lead Biosimilar Uptake with Value-Based Pathways

By Colin C. Edgerton, M.D. Biosimilar Adoption Falters Rheumatologists hoped that biosimilars would reduce the costs of treating diseases such as rheumatoid arthritis (RA), and thereby increase access to these life altering medications for our patients. The recent Forbes article, “Biosimilars Continue to Exhibit Market Failure” confirms what we as rheumatologists are observing, that biosimilars

Rheumatologists Lead Biosimilar Uptake with Value-Based Pathways Read More »

Recipients of Award to Assist with Workforce Expansion in Rheumatology

The field of rheumatology is experiencing a workforce shortage that is expected to worsen in years to come, and many patients living with rheumatic disease already live in medically underserved areas across the nation. Articularis Healthcare is proud to offer care with 12 locations across two states, spanning 11 counties. It’s not uncommon for patients

Recipients of Award to Assist with Workforce Expansion in Rheumatology Read More »

TSI Healthcare Partners with Articularis Rheumatology Network to Develop First Electronic Payer Approved RA Pathway

Originally published in PR Web TSI Healthcare, a national leader in the sales and support for NextGen Practice Management (PM) and Electronic Health Records (EHR) solutions partnered with Articularis Rheumatology Network to develop the first electronic payer approved Rheumatoid Arthritis (RA) Pathway. Articularis Rheumatology Network, together with TSI Healthcare, developed the clinical decision support pathway

TSI Healthcare Partners with Articularis Rheumatology Network to Develop First Electronic Payer Approved RA Pathway Read More »

Additional Arthritis Research Needed Among Veterans

Originally published in Veterans Health Today Colin C. Edgerton, MD, rheumatologist at Articularis Healthcare in South Carolina and chair of the American College of Rheumatology’s Committee on Rheumatologic Care and former US Army rheumatologist, discusses the prevalence of arthritis among active and former service members as well as the importance of a dedicated arthritis research

Additional Arthritis Research Needed Among Veterans Read More »

Is An Alternative Payment Model Just For Rheumatology Possible?

Originally published in March edition of News On Rheumatology Matters (NORM) The healthcare industry has been trying to shift away from the fee-for-service models that can incentivize overutilization towards payment models that reward quality – but these so-called “Alternative Payment Models” have been slow to catch on. However, some practices have embraced the core elements

Is An Alternative Payment Model Just For Rheumatology Possible? Read More »

Scroll to Top

How Can We Help You?